Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - Amarantus Bioscience Holdings, Inc. | v416954_ex99-1.htm |
| EX-99.2 - EXHIBIT 99.2 - Amarantus Bioscience Holdings, Inc. | v416954_ex99-2.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 3, 2015
AMARANTUS BIOSCIENCE HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
| Nevada | 000-55016 | 26-0690857 |
| (State or other jurisdiction of incorporation or organization) |
(Commission File Number) |
IRS Employer Identification No.) |
|
655 Montgomery Street, Suite 900 San Francisco, CA |
94111 |
| (Address of Principal Executive Offices) | (Zip Code) |
(408) 737-2734
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 7.01 | Regulation FD Disclosure |
Amarantus BioScience Holdings, Inc. (the “Company”) released a corporate presentation which it utilized during its Annual Meeting in New York on August 3, 2015. The Company’s presentation is furnished hereto as Exhibit 99.1.
The information disclosed under this Item 7.01, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as expressly set forth in such filing.
| Item 8.01 | Other Items |
On August 3, 2015, the Company issued a press release announcing that its August 3, 2015 Annual Meeting was adjourned due to lack of a quorum. A copy of the Company’s press release is furnished hereto as Exhibit 99.2.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
| Exhibit No. | Description | |
|
99.1 99.2 |
Presentation Amarantus Bioscience Holdings, Inc. Press Release, dated August 3, 2015 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| AMARANTUS BIOSCIENCE HOLDINGS, INC. | |||||
| Date: August 3, 2015 | By: | /s/ Gerald E. Commissiong | |||
| Name: Gerald E. Commissiong | |||||
| Title: Chief Executive Officer | |||||